More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Zoetis, ticker ZTS, and their third quarter 2026 results, which came out this morning.
**JORDAN:** Lots to unpack here — derm wars, screwworms, and a guy named Jay on his very first earnings call. Should be fun.
**ALEX:** It will be. But first, our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**JORDAN:** Good, now let's get into it.
**ALEX:** So Zoetis is the big animal health company — pet meds, livestock vaccines, diagnostics. Q3 revenue came in at $2.4 billion, down about 1% both reported and organically. That was basically in line with what management expected going in.
**JORDAN:** Adjusted EPS, though, actually ticked up 1% to $1.75, mostly thanks to a lower share count from buybacks, not operational strength. So it's a bit of financial engineering helping the bottom line while the top line stays soft.
**ALEX:** Right, and the U.S. segment was the weak spot — down 6% to $1.2 billion. International was actually the bright spot, up 4% to $1.1 billion, with livestock, parasiticides, and OA pain more than offsetting dermatology headwinds overseas.
**JORDAN:** And dermatology is really the story of this quarter. Key derm sales fell 16% globally to $396 million. In the U.S., Apoquel lost share to new competitors, though the chewable version is now half of Apoquel's volume, which shows some stickiness there.
**ALEX:** And Cytopoint actually held up better than expected — management said the new injectable competitor's impact was minimal so far, partly because that competitor has had supply issues.
**JORDAN:** Here's a stat that stuck with me: U.S. canine visits were down about 5%, pruritic — meaning itchy-skin — visits down 3%. So it's not just competition, it's genuinely softer clinic traffic. Pet owners are being more careful with spending.
**ALEX:** Which ties into something CEO Kristin Peck mentioned — vet service costs are up 50% since 2022, way outpacing general inflation. That's squeezing pet owners and changing behavior.
**JORDAN:** Right, and even the pet population mix is shifting — more cats, fewer dogs, because of housing costs affecting adoption. Dogs are more "medicalized," as they put it, so that mix shift actually weighs on demand for vet services overall.
**ALEX:** Now, the good news: management said their defensive playbook is working. They used targeted promotional spending — what they call "gross-to-net" investments rather than cutting list prices — to slow the bleeding. Derm share loss improved from 7 points lost in Q2 to just 4 points in Q3.
**JORDAN:** And in parasiticides, Simparica Trio held its U.S. share at 22.5%, still roughly double the next competitor, and they remain the leader in new puppy starts, which is a nice leading indicator for future sales.
**ALEX:** On the innovation front, there's real stuff coming. Long-acting Cytopoint is expected to get FDA approval in Q4, launching in the first half of 2027. Simparica Duo approval is now expected by year-end, ahead of schedule.
**JORDAN:** And don't skip over livestock — that segment grew 7% to $797 million, with strength in cattle, swine, poultry vaccines, and even fish vaccines in Norway. Global protein demand is just a steady tailwind there, offsetting the companion animal softness nicely. Diversification is really earning its keep this quarter.
**ALEX:** Diagnostics also grew double digits — 13% to $122 million — boosted by the VitalRADS and VPG acquisitions plus organic adoption of their point-of-care platforms.
**JORDAN:** Now let's talk guidance, because this is where it gets interesting. Zoetis narro
This episode includes AI-generated content.
Show More
Show Less